Switching from Immediate-Release to Extended-Release Guanfacine
Do not substitute immediate-release guanfacine for extended-release guanfacine on a mg-per-mg basis; instead, discontinue the immediate-release formulation and start extended-release guanfacine at 1 mg once daily, then titrate upward as needed. 1
Key Dosing Principle
The FDA-approved prescribing information for Intuniv (guanfacine extended-release) explicitly states: "Do not substitute for immediate-release guanfacine tablets on a mg-per-mg basis, because of differing pharmacokinetic profiles" 1. This is the most critical guidance for your clinical decision.
Recommended Conversion Approach
Step 1: Discontinue Immediate-Release Guanfacine
- Stop the current 1 mg immediate-release formulation
Step 2: Initiate Extended-Release at Standard Starting Dose
- Begin extended-release guanfacine at 1 mg once daily (morning or evening) 1
- This is the FDA-recommended starting dose regardless of prior immediate-release exposure
Step 3: Titration Strategy
- Adjust dose in increments of no more than 1 mg per week 1
- Target dose range: 1-4 mg once daily
- Consider weight-based dosing: improvements observed at 0.05-0.08 mg/kg once daily, with doses up to 0.12 mg/kg potentially providing additional benefit 1
Pharmacokinetic Rationale
The extended-release formulation has fundamentally different pharmacokinetics compared to immediate-release:
- Research evidence demonstrates that 3 mg/day of immediate-release guanfacine produces similar plasma levels to 4 mg/day of extended-release guanfacine after 24 hours 2
- This suggests the extended-release formulation requires higher total daily doses to achieve comparable drug exposure
- However, the FDA label prioritizes safety by mandating a fresh start at 1 mg regardless of prior dosing 1
Important Safety Considerations
Monitoring Requirements
- Measure heart rate and blood pressure before starting extended-release formulation and after each dose increase 3
- Extended-release guanfacine causes dose-dependent decreases in blood pressure and heart rate 3
Common Adverse Effects to Anticipate
- Somnolence, fatigue, dizziness, hypotension, and bradycardia are most common 4, 3
- These effects may be more pronounced during the initial titration period
Critical Pitfall to Avoid
Do not assume dose equivalence between formulations. The immediate-release formulation is dosed twice daily with different absorption characteristics, while extended-release provides once-daily coverage with modified pharmacokinetics 1, 5. Starting at an inappropriately high dose of extended-release based on the immediate-release dose could lead to excessive hypotension, bradycardia, or sedation.
Administration Details
- Do not crush, chew, or break tablets 1
- Avoid administration with high-fat meals due to increased drug exposure 1
Clinical Context
The guideline evidence confirms that guanfacine extended-release is dosed once daily at 1-4 mg, with weight-based considerations 3. For a patient previously on 1 mg immediate-release, starting at 1 mg extended-release provides a conservative, safe approach that allows for appropriate monitoring and subsequent titration based on clinical response and tolerability.